Permeability of aged grout around tunnels in London

Prediction of the long-term settlement of clay soils over tunnels requires a knowledge of the permeability of the soil and of the tunnel lining; however, determination of the lining permeability in the field is difficult. An important contributor to this problem is the lack of knowledge concerning the permeability of the grout between the lining and the soil. This paper presents the results of tests to characterise the properties of grout samples from London Underground tunnels, investigating permeability, porosity, micro structure and composition. The tests revealed that the newer grout was impermeable relative to the surrounding clay. However, the older samples showed much greater permeabilities and an altered grout composition, suggesting that degradation had taken place. Exposure to groundwater appeared to have caused carbonation and sulfate reaction. The combination of chemical reaction and leaching of cementitious and degradation products appears to have made these grouts more permeable, so that the grout could act as a drainage path rather than a barrier. This challenges the typical assumption that the grout acts as an impermeable barrier.

Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.

AIMS: Regenerative medicine is an emerging field with the potential to provide widespread improvement in healthcare and patient wellbeing via the delivery of therapies that can restore, regenerate or repair damaged tissue. As an industry, it could significantly contribute to economic growth if products are successfully commercialized. However, to date, relatively few products have reached the market owing to a variety of barriers, including a lack of funding and regulatory hurdles. The present study analyzes industry perceptions of the barriers to commercialization that currently impede the success of the regenerative medicine industry in the UK. MATERIALS & METHODS: The analysis is based on 20 interviews with leading industrialists in the field. RESULTS: The study revealed that scientific research in regenerative medicine is thriving in the UK. Unfortunately, lack of access to capital, regulatory hurdles, lack of clinical evidence leading to problems with reimbursement, as well as the culture of the NHS do not provide a good environment for the commercialization of regenerative medicine products. CONCLUSION: Policy interventions, including increased translational government funding, a change in NHS and NICE organization and policies, and regulatory clarity, would likely improve the general outcomes for the regenerative medicine industry in the UK.